Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Sees Strong Trading Volume – Should You Buy?

Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) shares saw strong trading volume on Friday . 200 shares were traded during trading, an increase of 9% from the previous session’s volume of 184 shares.The stock last traded at $58.75 and had previously closed at $56.95.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Kepler Capital Markets raised shares of Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 3rd. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 12th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Trading Up 5.1%

The firm’s 50-day moving average is $56.59 and its 200-day moving average is $61.72. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 1.13. The firm has a market cap of $12.12 billion, a price-to-earnings ratio of 22.23 and a beta of 0.26.

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.08 earnings per share (EPS) for the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 35.19%. The business had revenue of $834.86 million during the quarter.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.